The pain, nausea,
and vomiting endured by a patient undergoing chemotherapy can be
extremely debilitating. The number of medications that the healthcare
industry provides today can help with CINV, but do very little to
negate the symptoms. 2012 witnessed nearly 14.1 million people being
diagnosed with cancer, in comparison to the 12.7 million in 2008.
With the current rate in mind, the number is expected to reach 17.1
cancer patients by 2020. Their growing numbers will generate a high
demand from the healthcare industry for chemotherapy and related
markets, including the CINV drugs segment. With almost 70% to 80% of
chemotherapy patients experiencing nausea and vomiting, it has become
imperative to create stark improvements in the CINV existing and
pipeline drugs market.
Browse Full Global
CINV Existing and Pipeline Drugs Market Report With Complete TOC @
http://www.transparencymarketresearch.com/cinv-market.html
CINV Existing and
Pipeline Drugs Market Segmentation
The single strongest
point of differentiation in the market today is the association of
major drugs with their revenues earned. The list includes:
Akynzeo
(netupitant-palonosetron)
Kytril Generic
(granisetron)
Aloxi (palonosetron)
Zofran Generic
(ondansetron)
SUSTOL (extended
release granisetron injection)
Rolapitant
Emend (aprepitant)
Rolapitant and
SUSTOL (APF-530) are newly approved drugs that are set to drive the
CINV drugs market till 2020. They show a far stronger efficacy than
the current line of CINV drugs, in terms of their medical trials.
Their launch is expected to provide a boost to the CINV drugs market
and encourage physicians to prescribe the new drugs with a higher
confidence.
One the other hand,
drugs such as Aloxi and Emend are about to lose their patents to
expiration. This will have a significant impact on the CINV existing
and pipeline drugs market, which will be flooded with generic drugs
with the same chemical formula. The market’s revenue is expected to
go down largely due to this within a forecast period of 2014 to 2020.
Browse Full Press
Release:
http://www.transparencymarketresearch.com/pressrelease/cinv-market.htm
Geographical
Segmentation
The four prime
regions associated with the CINV existing and pipeline drugs market
are North America, Asia Pacific, Europe, and the Rest of the World.
Of these, North America has held the leading position in the market
in 2013 by generating the largest revenue. The region is expected to
stay as the market leader till 2020.
The second largest
region in the CINV existing and pipeline drugs market is Europe. An
average delay of one year is usually experienced by European
healthcare facilities in the launch of CINV drugs in comparison to
North America. The delays in release of Aloxi and Emend are something
that can be used to predict the region’s future in the market.
Asia Pacific is
expected to play a key role in the CINV existing and pipeline drugs
market in the coming years. The emerging economies of China and
India, along with a growing prevalence of cancer in the Asia Pacific
populace are bound to set the foundations of a strong CINV existing
and pipeline drugs market. The emerging nations are fast on the
tracks of establishing increasingly efficient healthcare
infrastructures. The eventual inclusion of more effective CINV drugs
will drive the region’s market further.
Key Companies
Most of the top
players in the CINV existing and pipeline drugs market are based in
North America and Europe. The list includes: Heron Therapeutics,
Inc., GlaxoSmithKline plc, Tesaro, Inc., Merck & Co., and Helsinn
Holding SA. Most of the top companies hold patented drugs in the CINV
existing and pipeline drugs market. Apart from them, the big
companies that manufacture generic drugs are Sun Pharma, Barr
Laboratories, Baxter Healthcare, Mylan Pharmaceuticals, Inc., Sandoz
(Novartis AG), Teva Pharmaceuticals, and Orchid Healthcare.
In conclusion, the
CINV existing and pipeline drugs market can expect steady growth due
to the rising incidences of caner and the arrival of new and more
efficient patented drugs. The market faces the challenge of patent
expiration and the efficacy of new patented drugs shall determine its
growth.
Request a Brochure
of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Mr.Nachiket
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment